OmniAb, Inc.
No SEC Form 4 filings for $OABI in the last 30 days.
See all $OABI insider activity →Investing.com reports OmniAb’s shares rose 22.5% in pre-open trading to $4.14, above its prior 52-week high of $3.635. The company announced a global collaboration and license with Eli Lilly for an ion channel drug discovery program, with an upfront payment and up to $370M in milestones plus tiered royalties. OmniAb also raised 2026 cash guidance to $49M-$53M from $37M-$41M.
OmniAb, Inc. (OABI) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 a2026q2ex991.htm EX-99.1 Document Exhibit 99.1 OmniAb Reports Second Quarter 2026 Financial Results and Business Highlights Raises Full Year 2026 Revenue and Cash Outlook Driven by Continued Business Momentum Conference Call to Begin Today at 4:30 p.m. ET EMERYVILLE, Ca
OmniAb Inc (NASDAQ:OABI) shares rose about 7.6% premarket after it named Amechi Nwachuku as Executive VP and Chief Operating Officer, a newly created role. He will oversee strategy, operations and commercial development of the xPloration B-cell screening platform. OmniAb said its licensing business remains strong with milestone and royalty programs.
Over the past 7 days, alphai's AI scored 1 news story mentioning OABI (OmniAb, Inc.). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent OABI coverage spans financial news, corporate actions and mergers & acquisitions.
The Eli Lilly collaboration terms and higher 2026 cash guidance are likely the immediate drivers of the pre-open surge and near-term repricing.
Raised 2026 revenue and cash outlook alongside improved cash position and lower net loss suggests improving fundamentals and reduced near-term funding risk.
Executive appointment is a near-term sentiment catalyst, but it does not disclose new financial guidance or product milestones.
Executive appointment and compensation package may affect near-term sentiment and governance expectations, but no operational or financial guidance is provided.
The 8-K discloses governance outcomes (board nominees elected; auditor ratified) but no new financial guidance or deal terms.
alphai scores every news story that mentions OABI with an AI model for sentiment and relevance, and aggregates insider trades from OmniAb, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Investing.com reports OmniAb’s shares rose 22.5% in pre-open trading to $4.14, above its prior 52-week high of $3.635. The company announced a global collaboration and license with Eli Lilly for an ion channel drug discovery program, with an upfront payment and up to $370M in milestones plus tiered royalties. OmniAb also raised 2026 cash guidance to $49M-$53M from $37M-$41M.
4 min readOmniAb, Inc. (OABI) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 a2026q2ex991.htm EX-99.1 Document Exhibit 99.1 OmniAb Reports Second Quarter 2026 Financial Results and Business Highlights Raises Full Year 2026 Revenue and Cash Outlook Driven by Continued Business Momentum Conference Call to Begin Today at 4:30 p.m. ET EMERYVILLE, Ca
6 min readOmniAb Inc (NASDAQ:OABI) shares rose about 7.6% premarket after it named Amechi Nwachuku as Executive VP and Chief Operating Officer, a newly created role. He will oversee strategy, operations and commercial development of the xPloration B-cell screening platform. OmniAb said its licensing business remains strong with milestone and royalty programs.
3 min readOmniAb, Inc. (OABI) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. oabi-20260713 FALSE 0001846253 Nasdaq 0001846253 2026-06-17 2026-06-17 0001846253 us-gaap:CommonStockMember 2026-06-17 2026-06-17 0001846253 us-gaap:WarrantMember 2026-06-17 2026-06-17 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ______________ FORM 8-K
2 min readOmniAb, Inc. (OABI) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. oabi-20260617 FALSE 0001846253 Nasdaq 0001846253 2026-06-17 2026-06-17 0001846253 us-gaap:CommonStockMember 2026-06-17 2026-06-17 0001846253 us-gaap:WarrantMember 2026-06-17 2026-06-17 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ______________ FORM 8-K
3 min readOmniAb (OABI) has updated its bylaws to align with SEC universal proxy rules, effective January 30, 2026. These revisions tighten disclosure and procedural requirements for shareholder nominations and business proposals, aiming to enhance transparency and reinforce the company's control over the nomination process. Despite significant financial challenges, OmniAb shows some optimism through positive technical indicators and strategic initiatives.
4 min readOmniAb, Inc. (OABI) delivered earnings and revenue surprises of 0.00% and -62.97%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
3 min readThe most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when prices go down.
4 min readOmniAb, Inc. (OABI) delivered earnings and revenue surprises of -7.14% and -35.71%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
3 min readOmniAb, Inc. (OABI) delivered earnings and revenue surprises of 0% and 11.50%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
3 min read
